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Abstract
Q fever is a worldwide zoonotic infectious disease due to Coxiella
burnetii. The clinical presentation may be acute (pneumonia and/or
hepatitis) or chronic (most commonly endocarditis). Diagnosis
mainly relies on serology and PCR. We therefore developed a
quantitative real-time PCR. We ﬁrst tested blindly its performance
on various clinical samples and then, when thoroughly validated,
we applied it during a 7-year period for the diagnosis of both acute
and persistent C. burnetii infection. Analytical sensitivity (< 10
copies/PCR) was excellent. When tested blindly on 183 samples,
the speciﬁcity of the PCR was 100% (142/142) and the sensitivity
was 71% (29/41). The sensitivity was 88% (7/8) on valvular
samples, 69% (20/29) on blood samples and 50% (2/4) on urine
samples. This new quantitative PCR was then successfully applied
for the diagnosis of acute Q fever and endovascular infection due
to C. burnetii, allowing the diagnosis of Q fever in six patients over
a 7-year period. During a local small cluster of cases, the PCR was
also applied to blood from 1355 blood donors; all were negative
conﬁrming the high speciﬁcity of this test. In conclusion, we
developed a highly speciﬁc method with excellent sensitivity,
which may be used on sera for the diagnosis of acute Q fever and
on various samples such as sera, valvular samples, aortic
specimens, bone and liver, for the diagnosis of persistent
C. burnetii infection.
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Introduction
Q fever is a worldwide zoonosis due to Coxiella burnetii, a small
pleomorphic gram-negative intracellular bacillus. Human infec-
tion is caused by inhalation of contaminated aerosols that can
spread by wind over some distance [1]. When infected
pregnant small ruminants abort, billion of C. burnetii end up in
the environment and fewer than ten organisms are sufﬁcient to
seed an infection [2]. The clinical presentation may be (i) acute
with inﬂuenza-like illness, hepatitis or pneumonia, or (ii)
chronic with mainly endocarditis [3]. Diagnosis still remains
challenging and relies mainly on serology, mostly performed by
indirect immunoﬂuorescence assay. However with serology it
is difﬁcult to make an early diagnosis, especially in acute
settings because it may occur during an epidemic.
In Switzerland, an important outbreak of human Q fever
occurred in 1983 in a Swiss Alpine valley [4] caused by ﬂocks
of sheep infected by C. burnetii. Some villages located near the
ﬂocks were strongly affected and the percentage of inhabitants
with acute Q fever was about 21%. Since that time, several
new outbreaks have been described, including a huge epidemic
in the Netherlands, with more than 4000 human cases notiﬁed
between 2007 and 2010 [5]. This large outbreak demonstrated
the importance of recognizing an epidemic early, through strict
veterinary surveillance and early recognition of acute Q fever
among humans. Serology is one of the current diagnostic
methods for Q fever, but it is obvious that the lag phase in
antibody response of 7–15 days after onset of clinical symp-
toms, is an important drawback of serology [5]. Conversely,
for the diagnosis of persistent C. burnetii infection, serology is
associated with a very high negative predictive value whereas
PCR may be applied to various samples such as cardiac valves,
aortic fragments and liver tissue, according to the respective
organ involved, so representing a pivotal tool to conﬁrm which
organ is affected.
In this context, we developed in 2005 an in-house diagnosis
real-time PCR that may be applied to various clinical speci-
mens including lower respiratory tract samples, blood, sera
and biopsies. We then assessed its analytical performance and
all respiratory specimens submitted to our diagnostic labora-
tory for Mycoplasma pneumoniae, Chlamydia pneumoniae and
Legionella pneumophila PCRs from 2005 to 2012 were
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prospectively analysed with the C. burnetii PCR. Specimens
from patients with suspected persistent C. burnetii infection
were also tested prospectively using our real-time PCR during
this 7-year period. Finally, in July 2012, in the context of a local
Q fever outbreak, we used this PCR to test all blood
donations to prevent transmission of C. burnetii via blood
transfusion. Hence, we report here our 7-year experience
with this new PCR initially validated at the analytical and
clinical levels.
Material and Methods
Development of the real-time C. burnetii PCR
Primers, probe and PCR settings. Primers and probe were
selected using PRIMER EXPRESS software (Applied Biosystems,
Foster City, CA, USA) from alignments of the available
sequences of the ompA gene using CLONE MANAGER 9 software
(Scientiﬁc & Education software, Cary, NC, USA). A forward
primer COX_F (5′-CAGAGCCGGGAGTCAAGCT-3′), a
reverse primer COX_R (5′-CTGAGTAGGAGATTTGAAT
CGC-3′), and a minor-groove binder probe labelled with 5′
TET(6-carboxyﬂuorescein) COX_probe (5′-CAGCCCTGC-
AGCGAGGAGCC-3′) were selected to amplify an 82-base-pair
fragment of the highly conserved region of the ompA gene.
The PCR were performed in a ﬁnal volume of 20 lL
containing 0.4 lM of each primer, 0.1 lM of probe, 10 lL of
29 Universal master mix (Applied Biosystems) and 5 lL of
extracted sample. The cycling conditions were 2 min at 50°C,
10 min at 95°C, followed by 45 cycles of 15 s at 95°C and
1 min at 60°C, during 45 cycles. The PCR products were
detected with an ABI Prism 7900 instrument (Applied
Biosystems). Since 1 April 2012, the Fast ABI Prism 7900
instrument was used, 7.5 lL of Fast advanced Master Mix
(Applied Biosystems) was used in each reaction and the cycling
conditions were 2 min at 50°C, 10 min at 95°C, followed by
45 cycles of 1 s at 95°C and 20 s at 60°C, during 45 cycles.
This fast PCR reduced the time of the PCR from 2 h and
20 min to 1 h.
Analytical sensitivity and speciﬁcity. To allow quantiﬁcation, a
plasmid containing the target was constructed as performed
previously [6]. To trace possible plasmid contamination the
insert was synthesized with four base modiﬁcations (R&D
Biotech, Besancon, France). These plasmids were run to
evaluate the analytical sensitivity and the intra-run and inter-run
reproducibility with samples containing ten-fold dilution from
1000 to ten copies of the positive control (plasmidDNA).When
the TaqMan Fast instrument was introduced, these controls
were run again to reassess the analytical sensitivity and the
robustness of the system. Moreover, the plasmids were used
routinely as positive controls in each run of PCR (1000, 100, 10
copies) and the cycle thresholds were introduced in a database
(multiQ system, developed by PhilippeMarquis, France) in order
to daily check the analytical sensitivity of the PCR.
DNA extraction. DNA was extracted using the MagnaPure LC
automated system (Roche, Rotkreuz, Switzerland) and the
MagNA Pure LC DNA isolation kit I (Roche) from 2005 to 1
February 2011. From this date, to increase the diagnostic
efﬁciency of our molecular diagnosis platform, the samples
were extracted using a full automation of nucleic acid
extraction with the dual STARlet (Hamilton, Bonaduz,
Switzerland)-MagNAPure 96 (Roche) system using the DNA
and viral NA small-volume kit with the PATHOGEN UNIVERSAL 2.0
protocol. This new system was evaluated before its use as
described earlier [7]. DNA was extracted from 200 lL of
specimen, i.e. EDTA-blood, sera, ground biopsies.
Validation of the C. burnetii PCR on clinical samples
Patients. First, we retrospectively analysed blindly eight paired
sera taken from four patients with acute Q fever, infected
during the 1983 Swiss outbreak and diagnosed as Q fever by
indirect immunoﬂuorescence assay. All four paired sera were
initially negative by serology and all seroconverted for IgM and/
or IgG phase 2 antigens.
To evaluate the sensitivity and speciﬁcity of the real-time
PCR, 123 extracted DNA from 66 EDTA-blood, 45 sera and
12 cardiac biopsies specimens (provided by Prof. Didier
Raoult) were tested blindly and the results were compared
to a nested PCR targeting the IS 1111 [8].
Pneumonia is the predominant presenting syndrome in
acute Q fever, we therefore analysed prospectively all 1046
respiratory specimens (111 sputa, 132 bronchial aspirations,
752 bronchoalveolar lavages, 20 nasopharyngial secretions, 19
endotracheal secretions, 12 pleural ﬂuids) for which Chlamydia
pneumoniae, M. pneumoniae or L. pneumophila were requested
by clinicians and that were referred to our laboratory from
2005 to 2012. Other specimens (48 EDTA-blood, 29 serum,
59 cardiac biopsies, 13 liver biopsies, 9 pulmonary biopsies and
19 other different specimens) from 101 patients with sus-
pected acute or persistent C. burnetii infection were addition-
ally tested prospectively, when requested by clinicians.
Blood donors. From 14 July to 20 August 2012, we had to test
in our high throughput platform, 2393 blood donations in a
prospective reactive way, to prevent Q fever transmission by
blood transfusion in the setting of a local Coxiella outbreak.
We received a mean of 100 specimens per day (minimum 50
and maximum 179 specimens) to be tested for C. burnetii by
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PCR within 24 h so that the blood could be used as quickly as
possible. This overwork was challenging and had to be carried
out in parallel with the routine diagnostic workload. In
practice, when the bar-coded EDTA blood tubes arrived in
the laboratory they were scanned using the STARlet liquid
handling system (Hamilton) and then 200 lL was transferred
to the bar-coded MagnaPure 96 Processing cartridge (Roche).
This step took 15 min to be completed for 95 specimens and
one negative extraction control. DNA was then extracted (1 h
for 96 specimens) and eluted in another bar-coded plate, i.e.
MagnaPure 96 output plate. Generally two runs per day were
completed.
The master mix was prepared manually each day and
distributed in a bar-coded microamp optical 384-well reaction
plate (Applied Biosystems) by the liquid handling system Tecan
Freedom Evo through the 2.4 SDS software (Applied Biosys-
tems). The DNA distribution in the 384-well plate was carried
out according to theHamiltonRobot EXCELmaster ﬁle through
Gemini (Tecan, M€annedorf, Switzerland). For each plate, two
sets of diluted plasmid-positive controls were added (1000, 100,
10 copies/PCR corresponding to 100 000, 10 000 and 1000
copies/mL of the initial sample). For each specimen, duplicates
were performed. Moreover a third well used as an inhibition
control was prepared by adding 200 copies of plasmid DNA (in
1 lL) to the DNA of each specimen (4 lL). One 384-well plate
was needed for 119 specimens, because three wells were
required per specimen and asmany as 27wells were used for the
positive and negative controls of the PCR. The set up of the plate
was performed in 100 min and ﬁnally the 384-well plate was
placed in the Fast ABI-Instrument for 55 min. The results were
read and checked on the 2.4 SDS in less than 15 min.
Results
Reproducibility, analytical sensitivity and speciﬁcity of the
PCR
To detect C. burnetii, a new quantitative real-time PCR was
developed that targets the ompA gene. This gene was chosen
given its high sequence conservation, as assessed by in silico
comparison of the seven available sequences in 2005, con-
ﬁrmed with 64 ompA sequences available in 2012. Analytical
speciﬁcity was excellent and no cross-ampliﬁcation was
observed when we tested the genomic DNA of humans
(Human genomic DNA, Roche), fungi (Candida albicans
ATCC10231, Aspergillus fumigatus clinical isolate), bacteria
(Bordetella pertussis clinical specimen, Chlamydia pneumoniae
ATCC VR-1310, Parachlamydia acanthamoebae ATCC
VR-1476, Escherichia coli ATCC 35218, Klebsiella pneumoniae
ATCC 27736, Haemophilus inﬂuenzae ATCC 49247, Haemo-
philus parainﬂuenzae ATCC 7901, Legionella pneumophila ATCC
33152, Mycoplasma pneumoniae ATCC 15293, Staphylococcus
aureus 29213, Staphylococcus epidermidis ATCC 14990, Strepto-
coccus pneumoniae ATCC 49619, Streptococcus pyogenes ATCC
19615, Streptococcus mitis ATCC 6249, Moraxella catharralis
ATCC 25238, Mycobacterium tuberculosis clinical specimen,
Pseudomonas aeruginosa ATCC 27853), and viruses (adenovirus
QAL-London, cytomegalovirus QAL-London, herpes simplex
type 1 clinical specimen, herpes simplex type 2 clinical
specimen, varicella zoster virus clinical specimen).
Then, a plasmid was constructed to assess the reproduc-
ibility of the PCR, to deﬁne the analytical sensitivity and to be
used as positive control. Sensitivity was ﬁrst determined by
testing duplicates of ten-fold serial dilutions of the plasmid in
independent experiments. The ten-fold diluted plasmids
corresponding to 1000, 100 and 10 copies per reaction
were always positive when tested in ten different runs with
Ct of 28.04  0.33, 31.56  0.24 and 35.11  0.71, respec-
tively. The 1 and 0.1 copy positive controls were only
positive in 5/10 and 3/10 PCRs with cycle threshold of
37.78  2.04 and 40.1  2.44, respectively. Hence the
analytical sensitivity is close to one copy and clearly better
than ten copies. To assess the intra-run and inter-run
variation observed during routine work, the data of the
plasmid positive controls were introduced from 1 January
2008 to 31 January 2012 in a MULTIQC WINDOWS software
application, a program that allows monitoring of the analytical
sensitivity of the PCR. During this 4-year period, 468 runs
were performed with the conventional ABI 7900 and the
1000 copies, 100 copies and 10 copies/reaction exhibited
medium cycle threshold values corresponding to
27.76  0.44, 30.97  0.51, 34.18  0.73, respectively; with
the new TaqMan Fast 7900, 80 runs were performed from 1
January 2012 to 1 August 2012 and the medium cycle
threshold values were 27.96  0.42, 31.13  0.42 and
34.42  0.78, showing the robustness of the analytical
sensitivity of the PCR run on two different instruments with
two different master mixes (Table 1).
TABLE 1. Analytical sensitivity and reproducibility of the
real-time PCR
Copies/reaction
Initial
validation of
the PCR
468 runs
1 January 2008
to 1 January
2012
80 runs
1 January 2012
to 1 August
2012
Ct mean SD Ct mean SD Ct mean SD
1000 28.04 0.33 27.76 0.44 27.96 0.42
100 31.56 0.24 30.97 0.51 31.13 0.42
10 35.11 0.71 34.18 0.73 34.42 0.78
1 37.78 2.04 nd – nd –
0.1 40.1 2.44 nd – nd –
Ct, Cycle threshold; SD, standard deviation; nd, not done.
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Retrospective validation on clinical samples
Among eight sera from four patients infected during the
outbreak of Q fever in 1983, all 4 initial sera negative by
serology were positive by PCR (cycle threshold : 32.04, 36.84,
38.04 and 40.69) whereas all four convalescent sera positive by
serology were all negative by PCR. This conﬁrmed that
real-time PCR may be useful for early diagnosis of acute Q
fever before seroconversion [5,8,9]. These sera had been
stored for 20 years and this long storage did not prevent the
positivity of the PCR.
We then assessed the sensitivity and speciﬁcity of the
real-time PCR on 66 EDTA-blood, 45 sera and 12 valvular
specimens. These 123 samples were tested blindly and the
results were compared with the nested PCR targeting the IS
1111 performed in Marseille as described elsewhere [8]
(Table 2). Real-time PCR was positive in three out of three
EDTA-blood samples that were positive with the nested PCR
and negative in 63 out of 63 EDTA-blood samples that were
negative by nested PCR. This shows a sensitivity and speciﬁcity of
100% in EDTA-blood samples. Cycle threshold values for the
three positive samples were 19.82, 27.17 and 34.04, corre-
sponding to high copy numbers per mL. For serum samples, 18
were positive by both PCR methods, whereas ﬁve were only
positive by the nested PCR and one was only positive by
real-time PCR, the other 21 serum samples were negative by
both PCR, showing a sensitivity of 78.3% and a speciﬁcity of
95.5% for serum samples when compared with the nested PCR.
For positive serum samples the mean Ct value was 36.46
(minimum33.74, maximum42.4) clearly lower than the values of
EDTA-blood samples, suggesting that EDTA-blood is a better
specimen than serum. Regarding the 12 valvular samples, ﬁve
were positive by both PCR, onewas positive only by nested PCR
and another one only by real-time PCR whereas ﬁve were
negative by both PCR. Sensitivity and speciﬁcitywere both 83.3%
but these are small numbers of specimens. For specimens that
were positive by both PCR, cycle threshold values were 15.41,
34.88, 34.04, 35.90, 36.40, respectively, corresponding to a
mean 31.32 (minimum 15.41; maximum 36.40), median of 34.88.
The relatively high mean and median of cycle threshold values of
serum samples could explain the lower sensitivity of the
real-time PCR for those specimens.
Prospective application to respiratory samples
During 7 years (2005 to 2012), 1046 respiratory samples (111
sputum, 132 bronchial aspirates, 752 bronchoalveolar lavage,
20 nasopharyngeal secretions, 19 endotracheal secretions and
12 pleural ﬂuids) were prospectively analysed by this new
C. burnetii real-time PCR. All were found to be negative
whereas 39 were found positive for Legionella pneumophila
PCR, 13 were positive for Mycoplasma pneumoniae PCR and
none were positive for Chlamydia pneumoniae PCR (Table 3).
Prospective application to specimens other than respiratory
samples
Among a total of 177 samples, the C. burnetii real-time PCR
was positive in 12 samples taken from six different patients:
seven cardiac biopsies, one serum, two inguinal biopsies, one
TABLE 2. Retrospective blind validation on 123 specimens of the new real-time PCR targeting the ompA gene using as gold
standard a nested PCR targeting the IS 111 gene
Nested PCR
IS 111
Real-time PCR
ompA n Sensitivity, % Speciﬁcity, % min–max Ct mean Ct median Ct
66 EDTA-blood + + 3 100 100 19.82–34.04 26.01 27.17
  63
45 serum + + 18 33.74–42.4 36.46 35.59
+  5
 + 1 78.3 95.5 34.88
  21
12 valvular biopsies + + 5 15.41–36.4 31.32 34.88
+  1 83.3 83.3
 + 1 37.94
  5
All + + 26
+ 6
+ 2 81.2 98
  89
The mean, median and minimum/maximum Ct values are also shown. Ct, Cycle threshold; n, number of samples.
TABLE 3. Prospective evaluation on 1046 respiratory sam-
ples*
Respiratory
specimens n
Coxiella
burnetii
Legionella
pneumophila
Mycoplasma
pneumoniae
Sputa 111 0 18 8
Bronchial
aspirates
132 0 7 0
Bronchoalveolar
lavage
752 0 9 4
Nasopharyngeal
secretions
20 0 0 1
Endotracheal
secretions
19 0 3 0
Pleural ﬂuids 12 0 2 0
*Note that all these 1046 samples have also been tested for Chlamydia pneumoniae,
but none were positive [31].
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intraoperative groin biopsy and one vertebral biopsy. The
clinical, microbiological and serological characteristics of these
six patients are summarized in Table 4. Four patients (patients
1–4) presented with endocarditis, one patient with a spond-
ylodiscitis and the last one had acute Q fever with isolated
granulomatous hepatitis. For this last patient, the ﬁrst serum
did not exhibit any anti-Coxiella antibodies but was positive by
PCR conﬁrming that PCR was positive earlier than serology.
High throughput application of the Coxiella PCR to blood
from blood donors
For 7 weeks (from 14 July until 30 August 2012) in the context
of a local outbreak (see Introduction) we had to test 2393
samples. Time to results had to be minimal because the stock
of blood was very low during the summer. Thanks to the
automated format of our molecular diagnostic platform, time
to get the results was less than 4 h for up to 96 specimens
(one run of extraction, Tecan distribution and TaqMan), less
than 5 h for up to 119 specimens (two runs of extraction, one
run of Tecan distribution and Taqman) and less than 7 h for up
to 179 specimens (two runs of extraction, Tecan distribution
and TaqMan). All the results were negative.
Discussion
Since the ﬁrst report of molecular methods for the detection of
C. burnetii, different PCR mainly targeting the IS 1111 have been
developed [10–16]. In Lausanne, a novel real-time PCR targeting
the ompA gene was developed to speciﬁcally detect C. burnetii
DNA in clinical samples. This new real-time PCR was sensitive
with an analytical sensitivity of at least ten plasmid DNA copies
per reaction and was highly reproducible. The high analytical
sensitivity of our real-time PCR was expected given the small
PCR products of the TaqMan format and the efﬁcient detection
thanks to a ﬂuorescent probe. Regarding the analytical speciﬁc-
ity, all DNA fromother pathogenswere negative, conﬁrming the
good speciﬁcity of the primers and probe. However, when
tested blindly the overall speciﬁcity was 98% (Table 2).
Conversely, the overall sensitivity ranged from 78.3% on serum
samples to 100% on EDTA-blood. This higher sensitivity on
EDTA-blood may be because the centrifugation steps used to
remove blood cells, when preparing sera, may also decrease the
total number of bacteria whereas EDTA-blood does not require
such a centrifugation step.
Early diagnosis of Q fever is important because delayed
diagnosis may lead to severe chronic infections such as
endocarditis and endovascular infections with high morbidity
and mortality [17–21]. As a matter of fact, despite the poor
performance of PCR on serum [9], sera are often used
instead of EDTA-blood because serum is often already
available for serology. To further validate our PCR on sera
from patients with acute Q fever, we also tested retrospec-
tive samples. All four seronegative initial sera from the former
Swiss outbreak of Q fever, were positive by PCR whereas all
the seropositive convalescence stage sera were negative. This
conﬁrmed that real-time PCR may be useful at the onset of
the disease [5,8,9,22] and that PCR positivity is directly
related to the absence of phase II antibody [23]. Regarding
the valvular biopsies, the sensitivity was 83.3%, which is
TABLE 4. Clinical characteristics and results of laboratory investigations of the six patients with a positive Coxiella PCR
Patient no. Age Sex Clinical presentation Laboratory ﬁndings Sample
Coxiella burnetii
PCR DNA copies/mL
(mean value Ct) Serology*
1 65 M Aortic prosthesis
infection
Ileofemoral abscess
Serum and EDTA-blood
negative by C. burnetii PCR
Femoro-iliac
abscess
260 (35.3) Ph1: IgG: 6 400; IgM: 0; IgA: 3 200
Aortic stent 1 19 900 (29.7) Ph2: IgG: 6 400; IgM: 0; IgA: 800
Aortic stent 2 184 000 (26.1)
Inguinal fragment 1 124 (37.9)
Inguinal fragment 2 3100 (33.0)
Intraoperative groin
biopsy
123 (36.6)
2 71 F Endocarditis Periaortic valve
abscess
3500 (32.3) Not available
Pus around aortic
valve
1 357 900 (24.7)
3 43 F Endocarditis Eubacterial PCR positive
for C. burnetii
Serum negative by C.
burnetii PCR
Aortic valve 1 000 000 (16.7) Ph1: IgG: 6400; IgM: 0; IgA: 200
Ph2: IgG: 12 800; IgM: 0; IgA: 400
4 53 H Aortic aneurysm Pseudoaneurysm
fragment
380 (36.0) Not available
5 57 M Spondylodiscitis Parafﬁn-embedded tissue
was also positive by PCR
L3–L4 vertebral
biopsy
18 969 (31.2) Ph1: IgG: 8192; IgM: 0; IgA: 0
Ph2: IgG: 4096; IgM: 0; IgA: 0
6 47 M Granulomatous
hepatitis
Serum** 390 (35) **Ph1: IgG: 0; IgM: 0; IgA: 0
Ph2: IgG: >640; IgM: 0; IgA:0
*Only highest titres are shown.
**Serology on initial serum was negative for C. burnetii. The PCR was only positive on ﬁrst serum
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excellent because sensitivity of eubacterial PCR is generally as
low as 60% [24]. Hence, valve biopsy represents an ideal
sample, when available, for the diagnosis of Coxiella endocar-
ditis [13].
During 7 years of clinical use, our PCR was positive on
various non-respiratory samples such as cardiac valve, aortic
aneurysm, liver biopsy and vertebral biopsy (Table 4), con-
gruent with manifestations of Q fever already reported in the
literature [3,21,25–28]. All these positive results were also
positive by serology, conﬁrming the excellent speciﬁcity of our
test over a 7-year period. Speciﬁcity of the PCR is also
supported by the negative results obtained on 1046 respira-
tory tract samples taken from patients with lung infections of
unknown aetiology.
Finally it has been shown that C. burnetii can survive and
remain infectious in blood products [29]. As this pathogen may
be present in blood during the ﬁrst weeks of infection,
C. burnetii may be present in donated human blood [30]. For
this reason, it was decided when an outbreak of Q fever
occurred close to Lausanne in June 2012 to test all blood
donations during a 2-month period. All tests were negative,
conﬁrming again the high speciﬁcity of our PCR. This large
screening prevented the exclusion of blood donations as a
precaution. Moreover this blood testing demonstrated the
usefulness of the automated format of our PCR platform.
In conclusion, we have developed a speciﬁc and sensitive
real-time PCR for the direct detection of C. burnetii DNA in
clinical samples that is compatible with our high throughput
Taqman real-time diagnostic PCR platform.
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